The commercial Institutional Review Board (IRB) landscape, historically dominated by small, owner-operated companies, has begun to rapidly consolidate over the past two years, signaling a different environment for ethical review and oversight of human subject projection in clinical trials going forward. This marketplace, which now has about three dozen commercial IRBs, is widely expected to continue consolidating until only four or five major players are left.
Lessons learned from medical device trials
The research industry has long been divided into two sectors: pharmaceuticals and devices. Though their differences are many, those who focus on devices say the pharma world can learn a great deal from this smaller, more nimble sector of the industry.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.
